{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.0","upperLimit":"14.0","value":"13.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Time to neutrophil engraftment will be analyzed by the Kaplan-Meier method. The time to engraftment of neutrophils is defined as the time from day 0 to the date of the first of three consecutive days after transplantation during which the absolute neutrophils count (ANC) is at least 0.5 x109/l. Patients who did not have neutrophil engraftment before death will be censored at the date of death. The median and 95% confidence intervals will be provided.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients administered 40 mg of basiliximab as a single intravenous dose on day +7, +8, or +9 following infusion of allogeneic peripheral blood hematopoietic cells","id":"OG000","title":"Overall"}],"paramType":"MEDIAN","populationDescription":"All patients enrolled and received treatment, excluding the patient who entered after the stopping rule was met.","reportingStatus":"POSTED","timeFrame":"Transplant (Day 0) up to 1 year","title":"Time to Neutrophil Engraftment","type":"SECONDARY","unitOfMeasure":"days"}